guidance.fyi
Company, ticker, metric, guidance, or anything said
VerifiedNumbers checked and claims independently audited

Q1 FY27 concall · earnings callYatharth Hospital & Trauma Care Services Limited

Yatharth delivered its highest ever quarterly revenue and profits, with 51% revenue growth driven by successful integration and rapid scaling of newer hospitals, while maintaining a focus on premium payer mix and expansion to 5,000 beds.

Positive tone4-minute briefPublished 9 days after the call

Numbers
MetricThis quarterChangeFive-quarter trend
Revenue₹392.7 Cr51% year-over-year
EBITDA₹91.7 Cr39% year-over-year
Consolidated EBITDA Margin23.3%—
Adjusted EBITDA Margin (ex-New Delhi & Faridabad S20)28.1%—
PAT₹45.4 Cr—
ARPOBINR34,7587% YoY
Financials

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹219.16 Cr+31.4% YoY+0.6% QoQ₹30.49 Cr+3.4% YoY-1.5% QoQ₹3.57-6.8% YoY-0.6% QoQ
Q2 FY25₹217.77 Cr+27.1% YoY+2.8% QoQ₹30.95 Cr+12.1% YoY+1.9% QoQ₹3.59-5.5% YoY+1.4% QoQ
Q1 FY25₹211.78 Cr+37.1% YoY+19.1% QoQ₹30.38 Cr+59.6% YoY-20.8% QoQ₹3.54+21.6% YoY-27% QoQ
Q4 FY24₹177.75 Cr— YoY+6.6% QoQ₹38.35 Cr— YoY+30% QoQ₹4.85— YoY+26.6% QoQ
Q3 FY24₹166.79 Cr— YoY-2.6% QoQ₹29.49 Cr— YoY+6.8% QoQ₹3.83— YoY+0.8% QoQ
TL;DR
  • Record quarterly revenue of INR3,927 million, up 51% YoY and 15% QoQ.
  • EBITDA grew 39% YoY to INR917 million; adjusted EBITDA margin (ex-new hospitals) at 28.1%.
  • Newer hospitals (Greater Faridabad, New Delhi, Faridabad Sector 20, Agra) contributed 27% of group revenue.
  • Faridabad Sector 20 hospital turned EBITDA breakeven within 9 months; New Delhi and Agra hospitals scaling well.
  • Group ARPOB reached all-time high of INR34,758, with premium NCR hospitals crossing INR50,000 mark.
  • Board approved maiden interim dividend of 5% and launched a new ESOP scheme.
Said on the call

“We delivered our highest ever quarterly revenue and profits this quarter.”

Yatharth Tyagi
From the Q&A
TopicWhat management said
Bed Capacity Target TimelineManagement clarified the 5,000 beds target will be achieved in less than three years (earlier than previously stated), with announced capacity already at 3,200 beds including Gurugram and brownfield expansions.
New Hospital Ramp-up & BreakevenFaridabad Sector 20 turned EBITDA breakeven in 9 months; New Delhi hospital is on track for breakeven between Q3-Q4 FY27. Occupancy calculations changed due to increased census beds, not stagnation.
EBITDA Margin TrajectoryWhile newer hospitals will improve, consolidated EBITDA margin is targeted upwards of 24% for FY27, not 28%, as new hospitals will continue to be added (e.g., Gurugram) creating ongoing drag.
Payer Mix & Government BusinessGovernment payer mix was ~40% for the quarter; increase of ~2% was due to CGHS rate revision, not volume. New hospitals have >90% cash/private insurance mix.
PAT Margin PressureLower PAT margins due to higher depreciation and interest costs from recent capex (Gurugram acquisition, oncology machines). Pressure expected to decrease as no similar high capex is planned soon.
Capex per Bed & FundingFuture capex per bed estimated at INR75-80 lakhs, funded by internal accruals and debt. Debt is comfortable at ~2x trailing EBITDA.
ARPOB GuidanceARPOB growth guidance of 8-10% YoY sustained; newer hospitals expected to reach 25%+ EBITDA margins within two years.
Guidance
  • FY27 revenue growth will surpass last year's 37% YoY growth.
  • FY27 EBITDA margin targeted upwards of 24%.
  • ARPOB growth expected at 9-10% YoY.
  • Target to reach 5,000 beds in less than three years.
  • Gurugram 250-bed facility expected to commence operations by Q1 FY28.
  • Expect to add at least one new hospital asset in FY27.
Source
Same sector

Others in Pharmaceuticals & Healthcare

All Pharmaceuticals & Healthcare →
  • Symbiotec Pharmalab LimitedQ1 FY27Positive tone

    Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.

    Consolidated revenue Q1 FY27
    ₹218 Crgrowth of 7% YoY
    API revenue Q1 FY27
    ₹215 Crgrowth of 6% YoY
    SYMBIOTECPharmaceuticals & HealthcareVerified brief6 guidance items
  • Molbio Diagnostics LimitedQ1 FY27Positive tone

    Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.

    Revenue from operations (Q1 FY27)
    ₹408 Cr
    EBITDA (Q1 FY27)
    ₹104 Cr
    MOLBIOPharmaceuticals & HealthcareVerified brief3 guidance items
  • Fischer Medical Ventures LtdQ1 FY27Neutral tone

    Fischer Medical Ventures used its September 7, 2026 investor call to present its AI-enabled imaging platform, proprietary technology stack and leadership team, without disclosing quarterly financial results.

    FISCHERPharmaceuticals & HealthcareVerified brief
  • Fortis Healthcare LimitedQ1 FY27Positive tone

    Delhi High Court ordered a court-supervised forensic audit into erstwhile promoter share dissipation, IHH's acquisition of control and use of funds for RHT assets, which Fortis and IHH say leaves operations, capex, bed expansion and M&A unrestricted and is expected to have no material adverse outcome.

    FORTISPharmaceuticals & HealthcareVerified brief4 guidance items
  • Orchid Pharma LimitedQ1 FY27Cautious tone

    Quarterly revenue improved 15% year-over-year and EBITDA grew on better gross margins, but the core cephalosporin business continues to face intense industry pricing pressure.

    Revenue from Operations
    ₹304 Crapprox. 15%
    Combined Gross Margin
    33%approx. 3% points
    ORCHPHARMAPharmaceuticals & HealthcareVerified brief6 guidance items